Islam R, Kundu S, Jha S, Rivera A, Flores Monar G, Islam H
Cureus. 2022; 14(4):e23785.
PMID: 35518552
PMC: 9063731.
DOI: 10.7759/cureus.23785.
Rangaswamy C, Mailer R, Englert H, Konrath S, Renne T
Semin Immunopathol. 2021; 43(4):507-517.
PMID: 34125270
PMC: 8202222.
DOI: 10.1007/s00281-021-00876-7.
Massoud O, Zein N
Gastroenterol Hepatol (N Y). 2017; 13(5):286-291.
PMID: 28656025
PMC: 5479341.
Rodriguez-Castro K, Antonello A, Ferrarese A
World J Hepatol. 2015; 7(14):1818-27.
PMID: 26207163
PMC: 4506939.
DOI: 10.4254/wjh.v7.i14.1818.
Hessien M, Ayad M, Ibrahim W, ulArab B
Indian J Clin Biochem. 2015; 30(2):210-6.
PMID: 25883431
PMC: 4393387.
DOI: 10.1007/s12291-014-0429-1.
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?.
Rossetto V, Spiezia L, Senzolo M, Rodriguez-Castro K, Gavasso S, Woodhams B
Intern Emerg Med. 2013; 9(4):397-403.
PMID: 23504244
DOI: 10.1007/s11739-013-0929-7.
Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases.
Marti-Carvajal A, Karakitsiou D, Salanti G
Cochrane Database Syst Rev. 2012; (3):CD004887.
PMID: 22419301
PMC: 11569891.
DOI: 10.1002/14651858.CD004887.pub3.
Assessment of validity of INR system for patients with liver disease associated with viral hepatitis.
Wei Y, Li J, Zhang L, Zheng D, Shi B, Cong Y
J Thromb Thrombolysis. 2009; 30(1):84-9.
PMID: 19915802
DOI: 10.1007/s11239-009-0423-2.
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.
Wei Y, Zheng D, Xiao L, Shi B
J Thromb Thrombolysis. 2009; 29(1):81-6.
PMID: 19330428
DOI: 10.1007/s11239-009-0330-6.
Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C.
Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T
Dig Dis Sci. 2007; 52(6):1535-9.
PMID: 17464564
DOI: 10.1007/s10620-006-9144-y.
New insights into the coagulopathy of liver disease and liver transplantation.
Senzolo M, Burra P, Cholongitas E, Burroughs A
World J Gastroenterol. 2007; 12(48):7725-36.
PMID: 17203512
PMC: 4087534.
DOI: 10.3748/wjg.v12.i48.7725.
Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.
Karasu Z, Gurakar A, Kerwin B, Hulagu S, Jazzar A, McFadden R
Dig Dis Sci. 2000; 45(10):1971-6.
PMID: 11117569
DOI: 10.1023/a:1005694617983.
Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis?.
Jabbour N, Zajko A, Orons P, Irish W, Fung J, Selby R
Dig Dis Sci. 1998; 43(11):2459-62.
PMID: 9824134
DOI: 10.1023/a:1026634215918.
Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis.
Lawrence S, Lezotte D, Durham J, Kumpe D, Everson G, Bilir B
Dig Dis Sci. 1995; 40(7):1575-80.
PMID: 7628285
DOI: 10.1007/BF02285211.
Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis.
Carmassi F, Morale M, De Negri F, Carrai M
J Mol Med (Berl). 1995; 73(2):89-93.
PMID: 7627635
DOI: 10.1007/BF00270583.
